Immune thrombocytopenia in 2 healthy young women after the Pfizer‐BioNTech BNT16B2b2 messenger RNA coronavirus disease 2019 vaccination. Issue 5 (17th September 2021)

• Record Type: Journal Article
• Authors: Collins, Emilie C.; Carr, Michael J.; Kim, James Soo; Lewis, John; Maleque, Noble; Desai, Krisha; Chen, Lauren; Sevransky, Jon; Gaddh, Manila; Rouphael, Nadine; Hubbard, Jacqueline; Pendley, Andrew M.
• Is Part Of: JACEP open. Volume 2:Issue 5(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-09-17
• Subjects: coronavirus disease 2019 vaccine -- ITP -- thrombocytopenia; Medical emergencies -- Periodicals; 616.025
• DOI: 10.1002/emp2.12531
• Languages: English
• ISSNs: 0361-1124

Abstract

Abstract: Immune thrombocytopenic purpura (ITP) is a rare complication associated with vaccines targeting various diseases, including influenza, measles‐mumps‐rubella, hepatitis B, and diphtheria‐tetanus‐pertussis. We report 2 cases of ITP in healthy 20‐year‐old and 21‐year‐old women presenting to Emory University in Atlanta, GA, 2 days after the second dose and 11 days after the first dose (respectively) of the Pfizer‐BioNTech messenger RNA severe acute respiratory syndrome coronavirus 2 vaccine. Both patients recovered quickly. With more than a billion doses of coronavirus disease 2019 vaccines safely administered worldwide as of May 2021, discussions with patients should put into perspective the low risks of vaccination against the enormous societal benefit of the coronavirus disease 2019 vaccine.